ROMVIMZA

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Feb 14, 2025

   1 yr 4 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Feb 14, 2030

   in 3 yr 9 mo

4. Patent 9181223 expires

   Listed drug substance patent expiration.

   Mar 14, 2034

   in 7 yr 10 mo

5. Patent 12285430 expires

   Listed method-of-use patent (U-4145) expiration.

   Dec 23, 2039

   in 13 yr 9 mo

6. Patent 12485120 expires

   Listed method-of-use patent (U-4145) expiration.

   Dec 23, 2039

   in 13 yr 9 mo

7. Patent 12582655 expires

   Listed method-of-use patent (U-4145) expiration.

   Dec 23, 2039

   in 13 yr 9 mo

8. Patent 11103507 expires

   Listed method-of-use patent (U-4145) expiration.

   Feb 03, 2040

   in 13 yr 10 mo

9. Patent 11679110 expires

   Listed method-of-use patent (U-4145) expiration.

   Feb 03, 2040

   in 13 yr 10 mo

10. Patent 12447149 expires

    Listed drug product patent expiration.

    Dec 06, 2044

    in 18 yr 9 mo

11. Patent 12528787 expires

    Listed drug substance patent expiration.

    Dec 06, 2044

    in 18 yr 9 mo

12. Patent 12551483 expires

    Listed drug product patent expiration.

    Dec 06, 2044

    in 18 yr 9 mo

13. Patent 12617775 expires

    Listed drug substance patent expiration.

    Dec 06, 2044

    in 18 yr 9 mo

14. Patent 12643883 expires

    Listed drug substance patent expiration.

    Dec 06, 2044

    in 18 yr 9 mo

15. Patent 12509443 expires

    Listed drug product patent expiration.

    Apr 30, 2045

    in 19 yr 2 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Feb 14, 2030

  in 3 yr 9 mo

Listed patents (12)